VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the stock.

VNRX has been the topic of a number of other research reports. HC Wainwright began coverage on VolitionRx in a research note on Tuesday, April 8th. They set a “buy” rating and a $2.50 price objective on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.33.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.50 on Friday. VolitionRx has a 52-week low of $0.42 and a 52-week high of $1.02. The company has a market cap of $50.59 million, a P/E ratio of -1.39 and a beta of 1.15. The stock’s 50-day simple moving average is $0.56 and its 200 day simple moving average is $0.62.

Insider Buying and Selling at VolitionRx

In related news, CEO Cameron John Reynolds acquired 181,818 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. The trade was a 8.59 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A number of large investors have recently made changes to their positions in the company. Lagoda Investment Management L.P. grew its holdings in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC increased its position in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the period. Millennium Management LLC acquired a new stake in VolitionRx in the 4th quarter worth about $36,000. Two Sigma Securities LLC bought a new stake in VolitionRx in the 4th quarter valued at about $29,000. Finally, Northern Trust Corp boosted its holdings in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.